U.S. Markets closed
  • S&P Futures

    3,926.25
    +3.50 (+0.09%)
     
  • Dow Futures

    31,475.00
    +35.00 (+0.11%)
     
  • Nasdaq Futures

    11,927.25
    -8.25 (-0.07%)
     
  • Russell 2000 Futures

    1,778.10
    +5.30 (+0.30%)
     
  • Crude Oil

    110.71
    +1.12 (+1.02%)
     
  • Gold

    1,814.00
    -1.90 (-0.10%)
     
  • Silver

    21.45
    -0.09 (-0.41%)
     
  • EUR/USD

    1.0502
    +0.0036 (+0.3466%)
     
  • 10-Yr Bond

    2.8860
    -0.0820 (-2.76%)
     
  • Vix

    30.96
    +4.86 (+18.62%)
     
  • GBP/USD

    1.2378
    +0.0036 (+0.2896%)
     
  • USD/JPY

    128.7380
    +0.4410 (+0.3437%)
     
  • BTC-USD

    29,194.92
    -673.96 (-2.26%)
     
  • CMC Crypto 200

    650.23
    -20.45 (-3.05%)
     
  • FTSE 100

    7,438.09
    -80.26 (-1.07%)
     
  • Nikkei 225

    26,238.40
    -672.80 (-2.50%)
     

Why Cortexyme Stock Imploded in 2021

·2 min read
Why Cortexyme Stock Imploded in 2021
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

The clinical-stage drugmaker's shares imploded last year in response to the failure of its lead Alzheimer's disease candidate atuzaginstat in a combined phase 2/3 study. Specifically, atuzaginstat reportedly missed both of its co-primary endpoints in the phase 2/3 Gain trial as a treatment for mild to moderate forms of Alzheimer's disease. Since announcing these disappointing trial results late last year, Cortexyme has said that it plans to trial the drug yet again.